- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04065035
A Clinical Study to Evaluate Efficacy and Tolerability of a Cosmetic Product for Arm Firming
A Double-Blind Split-Body Placebo-Controlled Clinical Study to Evaluate the Efficacy of a Cosmetic Product for Arm Firming
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This single-center, split-body, double-blind, randomized, controlled clinical trial is being conducted to assess the efficacy and tolerance of the topical firming body moisturizer when used over the course of 12 weeks by women with mild to moderate sagging, crepey skin, and overall photodamage on the upper arms.
Efficacy and tolerance will be assessed through clinical grading at baseline and weeks 4, 8, and 12. Efficacy will also be assessed through Corneometer and upper arm circumference measurements at baseline and weeks 4, 8, and 12, and Cutometer and Ultrasound measurements at baseline and weeks 8 and 12. Self-assessment questionnaires will be completed at baseline and week 12. Digital images will be taken at baseline and weeks 4, 8, and 12. Vectra H2 3D images will be taken at baseline and weeks 8 and 12. BMI will be measured at baseline and weeks 8 and 12. Biopsies will be collected from a subgroup of at least 10 subjects at baseline and week 12 (two biopsies on each arm at each time point; total of 8 per biopsy subject).
A total of 40 subjects completed study participation which included 10 subjects in the biopsy subgroup.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Richardson, Texas, United States, 75081
- Stephens and Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age range between 40 and 60 years
- Mild to moderate skin crepiness upper arm region
- Mild to moderate sagging skin upper arm region
- Mild to moderate overall photodamage upper arm region
- Willing to maintain their body weight within +/- 6.5 pounds
Exclusion Criteria:
- Diagnosed with known allergies to skin care products
- Who have had massive weight loss
- Who have undergone liposuction and/or weight loss surgery in the last 5 years.
- Who are nursing
- Who are pregnant
- History of skin cancer within the past 5 years.
- Having a health condition
- Having a history of immunosuppression/immune deficiency disorders
- Currently using oral or systemic immunosuppressive medications and biologics
- Currently using or having regularly used corticosteroids
- Having a disease such as asthma
- Having started a long-term medication within the last 2 months.
- Who started hormone replacement therapies (HRT)
- Having had brachioplasty (upper arm lift);
- Having liposuction
- Having cryolipolysis
- Having undergone a weight-loss diet or exercise habit change in the last 3 months or planning to start either during the study.
- Having used any of the indicated products or had any of the listed procedures on the upper arms within the indicated time frame prior to the study start date.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Topical Firming Body Moisturizer
Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
|
Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
Body cleanser to be used by study participants
Other Names:
Sunscreen to be applied after application of moisturizer
Other Names:
|
Placebo Comparator: Placebo Moisturizer
Oil-in-water emulsion base containing emollients.
|
Body cleanser to be used by study participants
Other Names:
Sunscreen to be applied after application of moisturizer
Other Names:
Placebo moisturizer is the vehicle control of the topical body firming moisturizer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Skin Crepiness Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin crepiness using a 10-point scale where none 0 = skin appears smooth with no crinkling to severe 9 = prominent, extensive crinkly texture at baseline, week 4, 8, and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Skin Elasticity Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin elasticity using a 10-point scale where none 0 = skin feels toned, dense and resilient to severe 9 = skin feels pliable, thin and nonresilient at baseline, week 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Skin Firmness Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin firmness using a 10-point scale where none 0 = skin appears very firm and feels thick to severe 9 = loose-appearing skin with poor stretch properties at baseline, week 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Skin Sagging Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin sagging using a 10-point scale where none 0 = no sagging, upper arm shows tight, lifted appearance to severe 9 = upper arm shows extreme sagging appearance at baseline, week 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Skin Roughness (Visual) Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin roughness (visual) using a 10-point scale where none 0 = smooth skin appearance, no roughness to severe 9 = pronounced reduction in skin smoothness appearance at baseline, week 4. 8, and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Skin Roughness (Tactile) Score
Time Frame: 12 weeks
|
Investigator assessed the participants' skin roughness (tactile) using a 10-point scale where none 0 = no palpable skin roughness, drag or surface bumps to severe 9 = significantly palpable skin roughness, drag, and surface bumps at baseline, week 4, 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Overall Photodamage Score
Time Frame: 12 weeks
|
Investigator assessed the participants' overall photodamage using a 10-point scale where none 0 = none or minimal visual evidence of photodamaged skin to severe 9 = severe photodamaged skin at baseline, week 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Evenness of Skin Tone Score
Time Frame: 12 weeks
|
Investigator assessed the participants' evenness of skin tone using a 10-point scale where none 0 = even skin color, no observable hyperpigmentation to severe 9 = significant detectable hyperpigmentation appearance at baseline, week 8 and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Evenness of Skin Redness Score
Time Frame: 12 weeks
|
Investigator assessed the participants' evenness of skin redness using a 10-point scale where none 0 = even skin tone to severe 9 = pronounced areas of redness at baseline, week 4, 8, and 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Objective Erythema Parameters
Time Frame: 12 weeks
|
Investigator assessed the participants' signs of erythema using a 4-point scale where none 0 = no erythema to severe 4 = marked redness at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Objective Edema Parameters
Time Frame: 12 weeks
|
Investigator assessed the participants' signs of edema using a 4-point scale where none 0 = no edema or swelling to severe 4 = marked edema at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Objective Dryness Parameters
Time Frame: 12 weeks
|
Investigator assessed the participants' signs of dryness using a 4-point scale where none 0 = no dryness to severe 4 = marked dryness at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Objective Peeling Parameters
Time Frame: 12 weeks
|
Investigator assessed the participants' signs of peeling using a 4-point scale where none 0 = no peeling to severe 4 = marked peeling at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Subjective Burning Parameters
Time Frame: 12 weeks
|
Participants assessed signs of burning using a 4-point scale where none 0 = no burning to severe 4 = hot burning sensation at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Subjective Stinging Parameters
Time Frame: 12 weeks
|
Participants assessed signs of stinging using a 4-point scale where none 0 = no stinging to severe 4 = marked stinging sensation at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Subjective Itching Parameters
Time Frame: 12 weeks
|
Participants assessed signs of itching using a 4-point scale where none 0 = no itching to severe 4 = marked itching sensation at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Change from Baseline in Subjective Tingling Parameters
Time Frame: 12 weeks
|
Participants assessed signs of tingling using a 4-point scale where none 0 = no tingling to severe 4 = marked tingling sensation at baseline and week 12.
A decrease in score indicates improvement.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lily Jiang, PhD, Thomas J. Stephens & Associates, Inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C18-D134
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Care
-
Eurofarma Laboratorios S.A.Not yet recruiting
-
LycoRed Ltd.CompletedSkin CareUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Power Life Sciences Inc.Not yet recruiting
-
Wayne State UniversityCompletedSkin CareUnited States
-
Marmara UniversityRecruiting
-
Eurofarma Laboratorios S.A.Not yet recruiting
-
Sakarya UniversityCompleted
Clinical Trials on Topical Body Firming Moisturizer
-
Cairo UniversityCompletedGastrostomy | Skin LaxityEgypt
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Memorial Sloan Kettering Cancer CenterIncyte Corporation; Hackensack Meridian HealthCompletedNon-sclerotic Cutaneous Chronic Graft-versus-host DiseaseUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)Withdrawn
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
Avicanna IncCompleted
-
Avicanna IncCompleted
-
University of UtahNot yet recruitingMetastatic Colon Cancer | Metastatic Rectum CancerUnited States
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States